USFDA okays Tocilizumab for treatment of Covid-19

The risk of patients being placed on ventilators or death was also decreased.

55

Last Updated on June 28, 2021 by The Health Master

Washington: The US Food and Drug Administration (USFDA) has issued an emergency use authorisation (EUA) for the drug Actemra (tocilizumab) — used for arthritis — for the treatment of hospitalised patients with Covid-19.

Under the EUA, the drug can be administered only to hospitalised adults and pediatric patients (2 years of age and older), receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). However, Actemra is not authorised for use in outpatients with Covid-19, the USFDA said in a statement.

USFDA
Picture: Pixabay

Clinical trials showed that administering Actemra to hospitalised Covid-19, in addition to routine care which included corticosteroid therapy, reduced the risk of death as well as decreased the amount of time patients remained hospitalised. The risk of patients being placed on ventilators or death was also decreased.

“Although vaccines have been successful in decreasing the number of patients with Covid-19 who require hospitalisation, providing additional therapies for those who do become hospitalised is an important step in combating this pandemic,” said Patrizia Cavazzoni, MD, Director of the USFDA’s Center for Drug Evaluation and Research.

Actemra is a monoclonal antibody that reduces inflammation and is given by intravenous infusion that is USFDA-approved for multiple inflammatory diseases, including rheumatoid arthritis.

Zydus Cadila gets tentative nod from USFDA for Pemetrexed for Injection

Cipla gets USFDA nod for Inhalation product

Zydus Cadila gets tentative nod from USFDA for Fingolimod Capsules

Alkem gets two observations from USFDA for USA plant

Lupin gets USFDA nod for treatment of Kidney patient

Aleor gets USFDA nod for Testosterone Topical Solution


In the case of Covid-19 infection, the immune system can become hyperactive, which may result in the worsening of the disease. But, Actemra does not directly target SARS-COV-2.

Based on the USFDA’s review of the totality of the scientific evidence available, the agency has determined that it is reasonable to believe that Actemra may be effective in treating Covid-19 for the authorised population. The data supporting this EUA for Actemra are based on four clinical trials. All four clinical trials contribute to the FDA’s understanding of Actemra for the treatment of Covid-19.

Common side effects of Actemra observed in the Covid-19 trials include constipation, anxiety, diarrhoea, insomnia, hypertension, and nausea. The EUA was issued to American biotechnology Genentech, a subsidiary of Swiss multinational healthcare Roche, USFDA said.

Copyright – An article (Part-1)

PCI releases draft syllabus for Diploma in Pharmacy

IPCA Lab gets CDSCO nod to conduct Phase-III study of HCQ

DCGI allows to conduct phase-III clinical trials on C-19 drug

Mankind, BDR Pharma to distribute Baricitinib in India

IPC to sensitize stakeholders on manufacturing of Quality Drugs

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner